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Use of High-Sensitivity Cardiac Troponin in Patients
With Kidney Impairment: A Randomized Clinical Trial
High-sensitivity cardiac troponin (hs-cTn) assays have im-
proved the diagnosis of myocardial infarction in patients with
healthy kidney function and
are now widely used in clini-
cal practice.1 However, in pa-
tients with kidney impair-
ment, long-term elevations in
troponin levels are common,
and interpretation can be more challenging.2 As such, the ef-
fect of implementing hs-cTn testing on the diagnosis and out-
comes of patients with kidney impairment is uncertain.
Methods | High-Sensitivity Troponin in the Evaluation of
Patients With Acute Coronary Syndrome (High-STEACS) was
a stepped-wedge, cluster-randomized clinical trial that evalu-
ated the use of a hs-cTnI assay in consecutive patients with
suspected acute coronary syndrome across 10 hospitals
(NCT01852123) (Supplement 1; eAppendix in Supplement 2).3
The trial was conducted in accordance with the Declaration of
Helsinki and with the approval of the Scotland Research Ethics
Committee, the Public Benefit and Privacy Panel for Health and
Social Care, and each National Health Service Health Board.
As randomization was at the hospital level, individual patient
consent was not sought. Throughout the trial, cTnI was
measured using contemporary and high-sensitivity assays
(ARCHITECTSTAT; Abbott Laboratories). Before use, results from
the hs-cTnI assay were suppressed, and the contemporary
assay (single threshold based on the coefficient of variation)
guided care. Sites were then randomly assigned to early or late
use of hs-cTnI testing, for which results from the contemporary
assay were suppressed and care was guided by the hs-cTnI
assay with sex-specific 99th percentile diagnostic thresholds.
Estimated glomerular filtration rate (eGFR) was calculated
using the Chronic Kidney Disease Epidemiology Collaboration
equation.KidneyimpairmentwasdefinedasaneGFRoflessthan
60 mL/min/1.73 m2. In this prespecified secondary analysis, the
primary outcome of subsequent type 1 or 4b myocardial infarc-
tion following the index presentation or cardiovascular death
within 1 year was compared before and after implementation of
the hs-cTnI assay in all patients with elevated hs-cTnI concen-
trations and in the subgroup of patients reclassified by hs-cTnI
testing with normal contemporary troponin concentrations, as
stratified by eGFR (<60/≥60 mL/min/1.73 m2) using Cox mod-
els that were adjusted for age, sex, phase, hospital site (random
effect), seasonality, presentation date, diabetes, ischemic heart
disease or cerebrovascular disease, hs-cTnI concentrations, and
deprivation status. Statistical analysis was performed in R, ver-
sion 3.6.1 (R Foundation). A 2-sided P value of less than .05 was
considered to indicate statistical significance.
Results | Across both phases, hs-cTnI concentrations were el-
evated in 10 111 of 46 927 patients (22%; mean [SD] age, 71 [15]
years; 4853 women [48%]), of whom 4220 (42%) had kidney
impairment. The proportion of patients with elevated hs-
cTnI concentrations increased as kidney function declined,
from 10% (1911 of 19 763) at an eGFR of 90 or greater to 66%
(1171 of 1766) at an eGFR of less than 30 mL/min/1.73 m2
(P < .001) (Figure, A). In contrast, the proportion of patients
with type 1 myocardial infarction decreased from 74% (1261 of
1709) to 35% (328 of 934) (P < .001) (Figure, B).
Following the use of hs-cTnI testing, the proportion of pa-
tients with an elevated troponin increased from 37% (1386 of
3721) to 47% (2503 of 5359) and from 13% (1918 of 14 686) to
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Figure. Myocardial Injury and Myocardial Infarction (MI) in Patients With Kidney Impairment
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A, Number of patients with high-sensitivity cardiac troponin concentrations
above and below the sex-specific 99th percentile across the entire study
population (n = 46 927) according to estimated glomerular filtration rate
(eGFR). B, Frequency of adjudicated diagnoses in patients with high-sensitivity
cardiac troponin concentrations above the sex-specific 99th percentile
(n = 10 111), according to eGFR.
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16% (3610 of 23 161) in those with and without kidney impair-
ment, respectively (P < .001 for both). Despite identifying more
patients at risk, the rate of subsequent type 1 or 4b myocar-
dial infarction or cardiovascular death at 1 year in all patients
with an elevated hs-cTnI concentration was similar before and
after use in those with (25% vs 24%; adjusted hazard ratio
[aHR], 1.00; 95% CI, 0.85-1.18) and without kidney impair-
ment (13% vs 11%; aHR, 0.89; 95% CI, 0.73-1.08) (Table). Simi-
larly, the primary outcome was unchanged in the subgroup of
reclassified patients in those with (18% vs 15%; aHR, 1.04; 95%
CI, 0.62-1.74) and without kidney impairment (12% vs 11%; aHR,
1.17; 95% CI, 0.69-1.96).
Discussion | While the frequency of elevated hs-cTnI concen-
trations increased 6-fold as kidney function declined from an
eGFR of 90 or greater to less than 30 mL/min/1.73 m2, the pro-
portion attributable to type 1 myocardial infarction halved. Al-
though hs-cTnI is effective at enabling the early rule out of myo-
cardial infarction in patients with kidney impairment,4,5 use
did not improve outcomes in patients with elevated levels
whether they had kidney impairment or not. The reasons for
this are complex. Two-thirds of patients with kidney impair-
ment and elevated hs-cTnI concentrations had a diagnosis
other than type 1 myocardial infarction. In the absence of evi-
dence from randomized trials, there is little guidance to in-
form clinical decisions for this heterogeneous group. More-
over, for those with kidney impairment and type 1 myocardial
infarction, the available evidence is largely extrapolated from
clinical trials in patients with broadly normal kidney function.6
Further research is therefore needed to convince clinicians of
the safety and efficacy of these treatments in patients with kid-
ney impairment. A limitation of this study is that it was not
possible to discriminate between acute and chronic kidney in-
jury. While both are associated with cardiovascular risk, these
conditions are distinct. Following the use of hs-cTnI testing in
clinical practice, 1 in 2 patients with kidney impairment had
an elevated troponin concentration, but these were less likely
due to myocardial infarction, and outcomes did not improve.
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Overall Before Use Overall After Use
No. of participants 4220 1717 2503 5891 2281 3610 10 111
Primary outcome
MI or cardiovascular deatha 1016 (24) 426 (25) 590 (24) 686 (12) 293 (13) 393 (11) 1702 (17)
Secondary outcomes
MIa 313 (7) 129 (8) 184 (7) 357 (6) 168 (7) 189 (5) 670 (7)
Unplanned revascularizationb 116 (3) 44 (3) 72 (3) 283 (5) 114 (5) 169 (5) 399 (4)
All-cause death 1500 (36) 662 (39) 838 (34) 808 (14) 353 (16) 455 (13) 2308 (23)
Death of cardiovascular causes 785 (19) 330 (19) 455 (18) 367 (6) 143 (6) 224 (6) 1152 (11)
Death of cardiac causes 630 (15) 261 (15) 369 (15) 294 (5) 113 (5) 181 (5) 924 (9)
Hospital admission for heart failure 601 (14) 250 (15) 351 (14) 396 (7) 195 (9) 201 (6) 997 (10)
Ischemic stroke 95 (2) 47 (3) 48 (2) 100 (2) 50 (2) 50 (1) 195 (2)
Safety end points
Major hemorrhagec 43 (1) 21 (1) 22 (1) 57 (1) 22 (1) 35 (1) 100 (1)
Unplanned hospital admission at 30 dd 1158 (27) 537 (31) 621 (25) 1805 (31) 820 (36) 985 (27) 2963 (29)
Noncardiovascular death 715 (17) 332 (19) 383 (15) 440 (8) 210 (9) 230 (6) 1155 (11)
Abbreviations: eGFR, estimated glomerular filtration rate;
hs-cTnI, high-sensitivity cardiac troponin; MI, myocardial infarction.
a Subsequent type 1 or type 4b MI.
b Defined as urgent or emergency percutaneous coronary intervention or
coronary artery bypass grafting from discharge to 1 year later.
c Bleeding Academic Research Consortium type 3 or type 5.
d Excludes type 1 or type 4b MI.
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Invited Commentary
High-Sensitivity Cardiac Troponin Assay
in Patients With Kidney Impairment:
A Challenge to Clinical Implementation
High-sensitivity cardiac troponin (hs-cTn) assay was ap-
proved by the US Food and Drug Administration in 2017,1 and
its appropriate use is currently being investigated. In this is-
sue of JAMA Internal Medicine, Gallacher et al2 examine the
use of hs-cTn assays in pa-
tients with kidney impair-
ment in a prespecified sec-
ondary analysis of a randomized clinical trial of patients with
suspected acute coronary syndrome (ACS). Their major find-
ing is that while the frequency of elevated levels of hs-cTn
increases as kidney function deteriorates, two-thirds of pa-
tients with kidney impairment and elevated hs-cTn concen-
trations do not have a type 1 myocardial infarction (MI re-
lated to coronary thrombosis). Despite the discovery of more
patients with elevated troponin levels by hs-cTn assays, 1-year
rates of a type 1 MI or type 4b MI (occurring ≤48 hours after
percutaneous coronary intervention) or cardiovascular death
were unchanged before and after implementation of hs-cTn
testing in patients with and without kidney impairment.
The scale of the challenge of hs-cTn testing implementa-
tion, combined with the challenge of interpreting elevated
hs-cTn values in patients with conditions that may produce
an elevated hs-cTn value not directly related to acute myo-
cardial injury (such as kidney impairment), is difficult to over-
state. Acute coronary syndrome is the leading cause of world-
wide mortality and morbidity, and chest pain—a symptom that
often triggers an ACS workup—is the second most frequent rea-
son for all US emergency department (ED) visits.3 Although a
minority of chest pain ED visits are related to ACS, the rate of
missed ACS after an ED evaluation is 2% to 4% and is associ-
ated with doubled mortality.4 Perhaps unsurprisingly, missed
ACS remains the top reason for malpractice claims against ED
physicians. Thus, there are enormously high stakes, both clini-
cally and medicolegally, for appropriate evaluation of pa-
tients with chest pain and use of hs-cTn testing to improve
efficiency of diagnosis and treatment without increasing un-
necessary testing and admissions.
This analysis by Gallacher et al2 highlights the need for
thoughtful use of hs-cTn testing, particularly in patients with
kidney impairment. While hs-cTn testing has acceptable
sensitivity as part of a workup to rule out MI,5 kidney impair-
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ment poses a particular challenge. Decreased kidney clear-
ance of troponin often results in elevated serum levels that do
not reflect true myocardial injury. However, patients with kid-
ney disease are at elevated risk for cardiovascular disease, and
kidney disease is often comorbid with conditions that are
cardiovascular risk factors, such as hypertension, dyslipid-
emia, and diabetes. Thus, there is a need to accurately detect
myocardial injury in this high-risk population, but the lower
specificity of hs-cTn testing compared with conventional tro-
ponin assays6 for all populations has the potential to trigger
unnecessary stress tests, angiograms, coronary revascular-
ization procedures, and admissions for all patients, and this
potential is particularly high in the population with kidney
impairment. Despite these challenges, it is not operationally
feasible to use different troponin assays (conventional vs
high sensitivity) for different patient populations; therefore,
this topic is pressing.
The hope for hs-cTn assays was both to enable earlier di-
agnosis of acute MI (type 1) than by conventional troponin
assays7 and to reduce costs and improve efficiency by allow-
ing more rapid discharge of low-risk patients,8 thereby help-
ing to relieve strained ED and hospital capacity by safely re-
ducing the number of patients with suspected ACS who are
admitted or observed for serial troponin measurements and
provocative cardiac testing. Many EDs have adopted proto-
cols to expedite diagnostics, such as laboratory or radio-
graphic testing. These protocol-driven evaluations, such as
standing nurse-driven chest pain triage protocols or physician-
in-triage models, have led to overuse of troponin assays in pa-
tients with low pretest probability of ACS. Adoption of hs-
cTn testing means that more patients—most who do not have
ACS—will have a falsely positive troponin result and undergo
protocol-driven but unnecessary additional testing or obser-
vation, particularly patients with kidney impairment, as shown
by Gallacher et al.2 Thus, adoption of hs-cTn assays may in-
crease resource utilization, including admission or observa-
tion, stress testing, and cardiology consultation, without ben-
efit to patient outcomes.
While much of the analysis on this topic centers on an
outcome of type 1 MI, the problem of elevated hs-cTn values
in patients with kidney impairment poses another challenge
for the ED physician: the diagnosis of type 2 MI (associated with
mismatches in myocardial oxygen supply and demand, rather
than coronary thrombosis) in patients with kidney impair-
ment and, in particular, when to treat patients with myocar-
dial oxygen supply-and-demand mismatch with heparin. While
this same problem existed prior to use of hs-cTn assays, the
relative increase in the proportion of patients with kidney
impairment who have elevated cardiac troponin values
increases with hs-cTn testing compared with conventional
troponin testing, meaning that the scale of this question is
greater. Does the clinician obtain serial values to determine the
delta, in which case the patient is at risk for further myocar-
dial damage during this interval? Or does the clinician initiate
anticoagulation, and all the risks entailed therein, in a patient
whose diagnosis is not yet clear? There is little established guid-
ance on these questions. While serial measurements will be
crucial in patients with kidney impairment to determine the
delta (or lack thereof) between the first and second troponin
measurements and therefore help to rule in or rule out MI, the
question of whether to make a diagnosis of type 2 MI after a
single hs-cTn measurement in a patient with kidney impair-
ment presenting with chest pain currently has no clear an-
swer. Clinicians will have to rely on the pretest probability of
myocardial injury, incorporating risk factors, medical his-
tory, and clinical gestalt, in making these early diagnostic and
treatment decisions.
The pressing question seems not to be how to interpret a
single hs-cTn value in a patient with kidney disease suspected
to have ACS, but rather to selectively order troponin testing in
patients with higher pretest likelihood of ACS and how to
integrate hs-cTn testing into the broader workup of such
patients. These questions include whether and at what inter-
val to obtain serial hs-cTn values, how to interpret the change
in value when obtaining serial hs-cTn measurements, and
how to weigh clinical factors, such as the patient’s age,
comorbidities, prior history of cardiovascular or cerebrovas-
cular disease, history and physical examination findings, and
electrocardiogram changes.
While the optimal strategy for management of myocar-
dial injury without ACS is unknown, it is clear that elevated
troponin levels are strongly related to increased long-term mor-
tality. Without a clearer understanding of elevated hs-cTn val-
ues in patients with kidney impairment and alternative risk
stratification tools that are easily implemented in the ED en-
vironment, such as a modified HEART score9 adapted to this
population, the clinical and medicolegal risks associated with
missed myocardial injury still favor a conservative approach
of increased testing and closer monitoring for those with el-
evated hs-cTn results.
Gallacher et al2 highlight the challenges that accompany
determining the appropriate use of hs-cTn assays. Further
research focused on the performance characteristics of com-
prehensive strategies to rule in and rule out suspected MI in
patients with kidney impairment, with an emphasis on com-
posite cardiac outcomes, is necessary to guide clinical imple-
mentation.
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Effectiveness of Tocilizumab in Patients
Hospitalized With COVID-19: A Follow-up
of the CORIMUNO-TOCI-1 Randomized Clinical Trial
Eight randomized clinical trials of tocilizumab for treating pa-
tients with COVID-19 have reported heterogeneous results.1-6 Al-
though 4 of them achieved their primary end point, improved
28-day survival was demon-
strated only in the 2 largest
studies and those with the
highest mortality, RECOVERY1 and REMAP-CAP.2 Moreover, only
RECOVERY enrolled only patients with elevated C-reactive pro-
tein (CRP) levels. The RECOVERY and REMAP-CAP trials in-
volved a high rate of patients using dexamethasone (>80% of the
patients in both treatment arms). Differences in trial outcomes
may be associated with differences in power, populations, de-
sign, management, or length of follow-up.
We previously published a trial of tocilizumab in hospi-
talized patients who were receiving oxygen (rate, ≥3 L/min) but
did not require high-flow or mechanical ventilation.3 The study
met its primary composite end point, which was the propor-
tion of patients who required noninvasive ventilation or intu-
bation or who died at day 14, but found no survival difference
at day 28. In this follow-up article, we extended follow-up to
90 days and examined whether survival varied with baseline
CRP levels.
Methods | The details of the trial have been previously re-
ported (Supplement 1 and Supplement 2).3 Institutional re-
view board approval was provided by Comités de Protection
des Personnes Île-de-France VI, and written informed con-
sent was gained. In this follow-up article, we compared sur-
vival at 3 months using random-effects Cox models that were
adjusted for age at randomization and center. We performed
a post-hoc analysis that was stratified by CRP. Statistical analy-
ses were conducted using R, version 3.6.4 (R Foundation).
Results | By day 90, death had occurred in 7 of 63 (11%) and 11
of 67 patients (18%) in the tocilizumab and usual care arms,
respectively (adjusted hazard ratio [HR], 0.64; 95% CI, 0.25-
1.65) (Figure). When outcomes were analyzed according to CRP
levels, we found a statistical interaction between CRP levels
and the primary composite end point at day 14 and survival
at day 90, with a benefit of tocilizumab in patients if their CRP
levels were greater than 15.0 mg/dL (to convert to mg/L, mul-
tiply by 10), but not if CRP levels were 15.0 mg/dL or less. In
patients with CRP levels greater than 15.0 mg/dL, the chance
of achieving the primary end point (the percentage of pa-
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CRP indicates C-reactive protein.
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